저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:

저작자표시. 귀하는 원작자를 표시해야 합니다.

비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.

변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리가 위의 내용에 의하여 영향을 받지 않습니다.

이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다.

Disclaimer
HOXA10 is Associated with Temozolomide Resistance through Regulation of the Homologous Recombinant DNA Repair Pathway in Glioblastoma Cell Lines

2015 년 2 월

서울대학교 대학원
의학과 신경외과학 박사과정
김 진 욥
A thesis of the Degree of Doctor of Philosophy

HOXA10 유전자와 상동체조합 DNA 복구기전 조절을 통한 교모세포중의 테모졸로마이드 항암요법의 치료 저항성 획득 기전 연구

HOXA10 is Associated with Temozolomide Resistance through Regulation of the Homologous Recombinant DNA Repair Pathway in Glioblastoma Cell Lines

February 2015

The Department of Neurosurgery, Seoul National University College of Medicine
Jin Wook Kim

HOXA10 유전자의 상동재조합 DNA 복구기전 조절을 통한 교모세포종의 테모졸로마이드 항암요법의 치료 저항성 횡득 기전 연구

지도교수 정희원

이 논문을 의학박사 학위논문으로 제출함.
2015년 1월

서울대학교 대학원
의학과 신경외과학 전공
김진욱

김진욱의 의학박사 학위논문을 인준함.
2015년 1월

위 원 장 김 일 한
부위 원 장 정 희 원
위 원 박 성 혜
위 원 박철기
HOXA10 is Associated with Temozolomide Resistance through Regulation of the Homologous Recombinant DNA Repair Pathway in Glioblastoma Cell Lines

by
Jin Wook Kim

A thesis submitted to the Department of Neurosurgery in partial fulfillment of the requirements for the Degree of Doctor of Philosophy in Neurosurgery at Seoul National University College of Medicine

January 2015

Approved by Thesis Committee:

Professor Il Han Kim Chairman
Professor Hee-Won Jung Vice chairman
Professor Sung Hye Park
Professor Chul-Kee Park

서울대학교

SEOUL NATIONAL UNIVERSITY
ABSTRACT

Introduction

Temozolomide resistance is associated with multiple DNA repair pathways. We investigated homeobox (HOX) genes for their role in temozolomide resistance, focusing on the homologous recombination (HR) pathway, and we tested their therapeutic implications in conjunction with O\(^6\)-methylguanine DNA methyltransferase (MGMT) status.

Methods

Two glioblastoma cell lines with different MGMT statuses were used to test the augmented anticancer effect of temozolomide with HOXA10 inhibition. In vitro experiments, including gene expression studies with RNA interference, were performed to verify the related pathway dynamics.

Results

HOXA10 inhibition reinforced temozolomide sensitivity independent of MGMT status and was related to the impaired double-strand DNA breakage repair process resulting from the downregulation of Rad51 paralogs. Early growth response 1 (EGR1) and phosphatase
and tensin homolog (PTEN) were the regulatory mediators between HOXA10 and the HR pathway. Moreover, HOXA10 inhibition selectively affected the nuclear function of PTEN without interfering with its cytoplasmic function of suppressing the phosphoinositide 3-kinase/Akt pathway.

Conclusions

The mechanism of HR pathway regulation by HOXA10 harbors another target mechanism for overcoming temozolomide resistance in glioblastoma patients.

-------------------------------------

Keywords: HOXA10, temozolomide resistance, homologous recombination, EGR1, PTEN

Student number: 2010-31140
CONTENTS

Abstract ..................................................................................................... 1
Contents..................................................................................................... 3
List of Figures ........................................................................................... 4
List of Tables ............................................................................................. 5
List of Abbreviations................................................................................. 6

Introduction........................................................................................ 7
Material and Methods...................................................................... 10
Results............................................................................................... 17
Discussion ......................................................................................... 33
Conclusion ........................................................................................ 37

References ............................................................................................... 38
Abstract in Korean.................................................................................. 45
LIST OF FIGURES

Figure 1 Result of MGMT promoter methylation-specific polymerase chain reaction. .......................................................... 18

Figure 2 Result of HOXA10 expression analysed by RT-PCR. Both LN18 and LN229 ................................................................. 19

Figure 3 Cell viability results presented as the relative cell death ratio. ........... 20

Figure 4 RT-PCR result after HOXA10 knockdown by siRNA. .................. 26

Figure 5 Western blot result after HOXA10 knockdown by siRNA. .......... 27

Figure 6 Result of cell viability test presented by relative cell death ratio. ... 28

Figure 7 RT-PCR result after HOXA10 knockdown by siRNA. ................. 30

Figure 8 Immunofluorescence image of γ-H2AX foci........................................ 31

Figure 9 Annexin V apoptosis assay in cancer cell lines by HOXA10 inhibition .............................................................. 32
LIST OF TABLES

Table 1 Primers used for PCR amplification ........................................... 12

Table 2 Identification of HOXA10-regulated genes in LN18 cells ................. 22
LIST OF ABBREVIATIONS

glioblastoma (GBM), O\textsuperscript{6}-methylguanine DNA methyltransferase (MGMT), mismatch repair (MMR), homologous recombination (HR), homeobox (HOX), phosphatase and tensin homolog (PTEN), polymerase chain reaction (MSP), reverse transcription-polymerase chain reaction (RT-PCR), small interfering RNA (siRNA), Temozolomide (TMZ), and O\textsuperscript{6}-benzylguanine (O\textsuperscript{6}-BG), DNA double-strand break (DSB), early growth response protein 1 (EGR1), phosphoinositide 3-kinase (PI3K),
INTRODUCTION

Temozolomide has been a mainstay of chemotherapy for glioblastoma (GBM) for the past decade but still produces unsatisfactory clinical outcomes. Most GBM patients who are treated with standard therapy incorporating temozolomide eventually experience progression, and only 11% of patents remain progression free at 2 years \(^1\). The inescapable early treatment failure rate of standard treatment largely depends on temozolomide resistance. From the perspective of the drug mechanism of temozolomide, O\(^6\)-methylguanine DNA methyltransferase (MGMT) has been proven to be associated with the prediction of the treatment effect \(^2\). However, there are further steps that lead the cancer cells to death after temozolomide treatment in relation to the DNA repair pathway, such as mismatch repair (MMR) and homologous recombination (HR) \(^3,4\). Temozolomide cytotoxicity is initially mediated by the generation of O\(^6\)-methylguanine from guanine, which can be repaired by MGMT \(^5\). However, unrepaired O\(^6\)-methylguanine successively results in thymine mispairing during DNA replication, and these mispairs result in futile cycles of the repair process by the MMR system due to the persistence of O\(^6\)-methylguanine in the template strand \(^5\). These futile cycles of the DNA repair process eventually cause double-strand DNA breaks, leading to cell apoptosis if the HR system functions
inadequately \textsuperscript{5}. Therefore, temozolomide resistance can be induced if MGMT is activated, MMR function is defective, or HR is normal. In addition to the established mechanism of temozolomide resistance by MGMT, reports have been published concerning inactivating mutations of MSH6 among MMR genes contributing to temozolomide resistance in GBM \textsuperscript{6-8}. However, the incidence of MMR alterations in GBM is infrequent; thus, it is considered to be less important for temozolomide resistance \textsuperscript{3, 9}. Otherwise, the contribution of HR to temozolomide resistance has been rarely studied, and little is known. We investigated temozolomide resistance and mechanisms to restore temozolomide sensitivity, focusing simultaneously on MGMT and HR.

To identify plausible targets for temozolomide resistance, we considered homeobox (HOX) genes, which showed a significant relationship between its dichotomized sub-classification with MGMT and survival in gene expression profiling studies, as previously reported \textsuperscript{10}. HOX genes are a group of essential regulatory genes that normally control embryonic development and that should be in the silenced state in the adult central nervous system \textsuperscript{11-13}. Recent studies have shown evidence of the aberrant expression of HOX genes in diverse cancers, including gliomas \textsuperscript{14-18}. Although solid evidence exists concerning the role of HOX genes in oncogenesis and therapeutic resistance in gliomas, the exact mechanism remains unclear, and only a small number of
recent studies have been published \textsuperscript{9, 10, 18}. In the present study, we investigated the mechanism of HOXA10 regarding its role in temozolomide resistance using glioblastoma cell lines and tested the therapeutic implication of temozolomide resistance in conjunction with MGMT status. The result of the present study suggests a possible hypothesis for the temozolomide non-responders in MGMT-inactive GBM patients.
MATERIALS AND METHODS

Cell lines

The human glioma LN18 and LN229 cell lines were obtained and cultured in DMEM containing 10% fetal bovine serum and 5% antibiotics (streptomycin) in a humidified atmosphere of 5% CO₂ and 95% air at 37°C. Both cell lines express wild-type phosphatase and tensin homolog (PTEN) as described previously ¹⁹. We performed methylation-specific polymerase chain reaction (MSP) to confirm the methylation status of the MGMT promoter after DNA isolation and bisulfite treatment in these cell lines as described previously ²⁰.

mRNA expression

The primers used were designed using the primer-BLAST tool available on-line (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The primer sequence of HOXA10, EGR1, PTEN, Rad51b, Rad51c, Rad51d, and GAPDH are summarized (Table 1). Using these primers, reverse transcription-polymerase chain reaction (RT-PCR) was performed to evaluate their expression. Cell lines were lysed with TRIzol (Life technologies), and RNA isolation was performed using an RNeasy Mini Kit (QIAGEN, #74104). Total RNA was treated with DNase and then quantified by spectrophotometry. Additionally, cDNA
was synthesized from 1 µg of total RNA using a reverse transcription kit (QIAGEN, #205311) according to the manufacturer’s procedure. The RT-PCR reaction was carried out for 35 cycles, comprising 95°C for 5 min, 95°C for 30 sec, and 58°C for 30 sec with each primer set. RT-PCR products were resolved by 2% agarose gel electrophoresis, and the bands were quantified using image analyzing software (ImageJ v1.47; http://rsb.info.nih.gov/ij/).
**Table 1**

Primers used for PCR amplification.

| Forward (5’→3’) | Reverse (5’→3’) | Amplicon length (bp) |
|----------------|-----------------|----------------------|
| HOXA10         | AGGTGGACGCTGCAGCTAATCTCTA | GCCCCTTTCGAGAGCAGCAAG | 209 |
| EGR1           | CTGCACGCTTTCAGTTCCGA | CGAGTGAGGAAAGGATCCGA | 210 |
| PTEN           | TGGAAAGGACGACTGGTG | CACCTTTAGCAGCCAGACCA | 289 |
| Rad51b         | TGTGGTGAACACATCCCATCGT | TGTTCCACGAACACACAAACCA | 255 |
| Rad51c         | TTGTTGAGTTCCCGCTGT | ACCCACCCTTAAAAGGAGAACA | 399 |
| Rad51d         | GAATGGCCTGATCTCTACGA | TCTCCTGGAAAACCTGTGGC | 725 |
| GAPDH          | GCAGGGGGGAGCCAAAGGG | TGCCAGCCAGCGTCAAAG | 450 |
RNA interference

For small interfering RNA (siRNA) experiments, commercially available sequences targeting HOXA10 (iHOX; Sigma Aldrich, #SASI_Hs01_00172491) and PTEN (iPTEN; Dharmacon, #L-003023-00-0005) as well as nontargeting control siRNAs (Dharmacon, #D-001610-01-05) were used. At 70–80% confluence, the cells were transfected with siRNAs at the most efficient transfection condition determined by the NEON® Transfection system (Life Technologies, #MPK5000). The cells were cultured in media without antibiotics to increase the siRNA transfection efficiency for 24 hours.

Drug treatment and cell viability analysis

Normal and transfected cells were grown on 96-well plates at a density of 4x10³ cells per well for 24 hours. Temozolomide (TMZ; Enzo, #420-044-M100) and O⁶-benzylguanine (O⁶-BG; Sigma Aldrich, #B2292-50MG) were treated with a final concentration of 1000 µg/ml and 300 µg/ml for 24 hours, respectively. Cell viability analysis was performed using a Colorimetric Cell Counting kit-8 (CCK; Dojindo Molecular Technologies). Quantification of viable cells was performed by the reading of ultraviolet (UV) absorption spectra at 450 nm on a microplate 2 hours after adding 10 µl of CCK solution per well according to the manufacturer’s instructions. All experiments were
conducted in triplicate.

**Gene expression profiling**

Samples of the LN18 cell line transduced with siHOXA10 as well as control siRNA for 24 hours were analyzed using Affymetrix GeneChip Human Gene 1.0ST Arrays (Affymetrix) to identify the gene expression changes before and after HOXA10 knockdown. Expression data were normalized using the robust multi-array average (RMA) method. Affymetrix Expression Console Version 1.1 (Affymetrix) was used to compare the group signals, and data were log-transformed (base 2) for parametric analysis. Differentially expressed genes were identified using significance analysis of microarrays (SAM) with the R package ‘samr’ (R 2.11.1).

**Protein detection**

Whole protein extracts of the cells for western blotting were prepared using PRO-PREP lysis buffer (Intron, #17081), and protein concentrations were determined using the BCA protein assay (Thermo Fisher Scientific, #23227). Proteins were separated by 10% SDS-PAGE, blotted onto nitrocellulose membranes, and then probed with antibodies against total AKT (Genetex, #GTX121937, 1:3000 dilution), phosphorylated AKT (Genetex #GTX61708, 1:2000 dilution), total
PTEN (Genetex, #GTX101025, 1:500 dilution), and phosphorylated PTEN (Genetex, #GTX61780, 1:1000 dilution). The membranes were then incubated with a goat anti-rabbit IgG secondary antibody (Jackson, #003318367, 1:4000 dilution) for 1 hour. The membranes were incubated in ECL-prime solution (GE Healthcare Amersham, #RPN2232) in the dark for 1 minute and then exposed under a fluorchemHD2 (Cell biosciences) for visualization.

**DNA double-strand break assay**

The DNA double-strand break (DSB) rates were assessed by quantifying the rates of $\gamma$-H2AX foci. Approximately $5 \times 10^4$ cells were seeded on coverslips after drug treatment and were cultured overnight in a 37°C incubator without antibiotics. The following day, cells were fixed with 100% cold methanol for 5 minutes and then permeabilized with 0.25% PBST for 20 minutes. Next, the cells were incubated in 5% skim milk to block non-specific protein-protein interactions and immunostained with a $\gamma$-H2AX primary antibody (Abcam, #ab22551) and an FITC-conjugated rabbit anti-mouse secondary antibody (Invitrogen, #A11029). The number of $\gamma$-H2AX foci with DAPI was determined using a fluorescence microscope (100× objective). Disrupted cells were excluded from the analysis. Foci counting was performed for an average of 50 cells. The mean number of foci per cell
was scored, and the standard error of the mean was calculated.

**Apoptosis assay**

For apoptosis assays, cells were harvested and suspended in annexin V-binding buffer (BD Biosciences, #556570) at a concentration of $1 \times 10^5$ cells/100 µl. Next, 5 µl of annexin V-FITC and 5 µl of propidium iodide (PI) were added to each sample, and the samples were incubated in the dark at room temperature for 15 min. The samples were run through a FACScan flow cytometer (BD-FACSCalibur-2, #633488), and annexin V positive and PI negative cells were designated apoptotic.

**Statistical analysis**

ANOVA and Student's t test were used to identify significant differences in the cell death rate, DSB assay, and apoptosis experiments. The results were analyzed using IBM SPSS Statistics software (version 19.0; SPSS, Inc.). Data are presented as the mean ± standard deviation (SD) of three or more separate experiments, and a P value of 0.05 was considered to be statistically significant.
RESULTS

**HOXA10 mediates temozolomide resistance independent of MGMT**

The MGMT methylation status of the LN18 and LN229 glioma cell lines as measured by MSP revealed an unmethylated MGMT promoter (MGMT active) for LN18 cells and a methylated MGMT promoter (MGMT inactive) for LN229 cells (Figure 1). Both cell lines displayed intact HOXA10 expression, which was successfully knocked down with iHOXA10 (Figure 2). When the cell lines were treated with TMZ in combination with O\(^6\)- BG and/or iHOXA10, significant differences in the cell death ratio were observed when iHOXA10 was added (Figure 3). This additive effect of iHOXA10 on cell viability was independent of the MGMT status and created an added effect over MGMT inhibition.
Figure 1

Result of MGMT promoter methylation-specific polymerase chain reaction. Each lanes with asterisk indicate control DNAs for unmethylation and methylation. MGMT promoter is unmethylated in LN18 and methylated in LN229.
Figure 2

Result of HOXA10 expression analysed by RT-PCR. Both LN18 and LN229 shows expression of HOXA10 and they are successfully supressed by siRNA treatment.
Figure 3

Cell viability results presented as the relative cell death ratio. Inhibition of HOXA10 shows an additive effect with temozolomide treatment in both cell lines, even after the inhibition of MGMT in LN18 cells.
Screening for effectors of HOXA10

To identify HOXA10-regulated genes, we transduced LN18 cells with control siRNA or HOXA10-silencing siRNA (iHOXA10) and carried out microarray gene expression profiling. We compared the expression values of selected probe sets displaying average fold-changes of at least 2.0-fold, yielding 124 probe sets as being differentially expressed (15 up- and 109 down-regulated). Among them, only selected genes with RefSeq identifiers (NCBI Reference Sequence Database; http://www.ncbi.nlm.nih.gov/refseq/) are listed (Table 2). We then used the functional annotation tools within DAVID Bioinformatics Resources (http://david.abcc.ncifcrf.gov/home.jsp) to perform gene annotation enrichment. This analysis indicated that early growth response protein 1 (EGR1) is a mediator for the functional category of transcription/cell division and chromosome partitioning among the listed genes. EGR1 showed a -3.09-fold change after iHOXA10 treatment. After thorough review of the functions of EGR1, we focused on previous reports indicating that EGR1 induces phosphatase and tensin homolog (PTEN) by regulating its promoter. Moreover, evidence has shown that PTEN has novel nuclear functions, including transcriptional regulation of the Rad51 gene, whose product is essential for HR repair of DNA breaks. Therefore, we hypothesized that HOXA10 can regulate the HR system mediated by EGR1 and PTEN.
Table 2

Identification of HOXA10-regulated genes in LN18 cells. HOXA10-silencing siRNA versus control siRNA transduced cells are compared using Affymetrix GeneChip Human Gene 1.0ST Arrays. Probe sets with fold-changes of more than 2-fold are shown (3 up and 54 down probe sets).

| Gene Accession | Gene Symbol | log2 ratio (control vs iHOXA10) | Fold change |
|----------------|-------------|---------------------------------|-------------|
| **Up regulation** |             |                                 |             |
| 1 NM_001771  | CD22        | 1.37                            | 2.58        |
| 2 NM_001042390 | PTPN20A     | 1.38                            | 2.60        |
| 3 NM_001143818 | SERPINB2    | 1.51                            | 2.85        |
| **Down regulation** |         |                                 |             |
| 1 NM_001166292 | PTCH2       | -1.87                           | 3.65        |
| 2 NR_002979  | SNORA49     | -1.79                           | 3.46        |
| 3 NR_002960  | SNORA20     | -1.79                           | 3.45        |
| 4 NR_003706  | SNORA38B    | -1.79                           | 3.45        |
| 5 NR_000018  | SNORD35A    | -1.76                           | 3.39        |
| 6 NR_003035  | SNORA16A    | -1.71                           | 3.28        |
| 7 NM_014997  | KLHDC10     | -1.06                           | 2.08        |
| 8 NM_015886  | PI15        | -1.69                           | 3.23        |
| 9 NM_032290  | ANKRD32     | -1.65                           | 3.15        |
|   | Gene Symbol | Gene Name | Log2 Fold Change | p-Value |
|---|-------------|-----------|-----------------|---------|
| 10 | NM_001964   | EGR1      | -1.63           | 3.09    |
| 11 | NR_023343   | RNU4ATAC  | -1.60           | 3.04    |
| 12 | NR_003137   | RNU4-2    | -1.57           | 2.97    |
| 13 | NR_002963   | SNORA24   | -1.55           | 2.92    |
| 14 | NM_001030   | RPS27     | -1.05           | 2.07    |
| 15 | NR_002911   | SNORA71A  | -1.54           | 2.90    |
| 16 | NM_001866   | COX7B     | -1.43           | 2.70    |
| 17 | NM_005063   | SCD       | -1.43           | 2.70    |
| 18 | NR_003041   | SNORD13   | -1.40           | 2.64    |
| 19 | NR_003041   | SNORD13   | -1.39           | 2.63    |
| 20 | NR_002749   | SNORD45A  | -1.37           | 2.58    |
| 21 | NR_002962   | SNORA23   | -1.34           | 2.53    |
| 22 | NR_002447   | SNORD24   | -1.30           | 2.47    |
| 23 | NM_152997   | C4orf7    | -1.28           | 2.43    |
| 24 | NR_000020   | SNORD33   | -1.26           | 2.40    |
| 25 | NR_002748   | SNORD45B  | -1.26           | 2.40    |
| 26 | NM_001030   | RPS27     | -1.19           | 2.28    |
| 27 | NR_003018   | SNORA71D  | -1.18           | 2.27    |
| 28 | NR_002580   | SNORA3    | -1.18           | 2.26    |
| 29 | NM_004891   | MRPL33    | -1.17           | 2.25    |
| 30 | NR_002569   | SCARNA9   | -1.04           | 2.06    |
| 31 | NM_182511   | CBLN2     | -1.16           | 2.23    |
| 32 | NR_004381   | SNORD105  | -1.14           | 2.21    |
| 33 | NR_000021   | SNORD32A  | -1.14           | 2.21    |
| 34 | NR_000019   | SNORD34   | -1.14           | 2.20    |
| 35 | NR_003002   | SCARNA13  | -1.14           | 2.20    |
| No. | Accession   | Gene Name | Expression Ratio |
|-----|-------------|-----------|------------------|
| 36  | NM_019058   | DDIT4     | -1.12            | 2.17            |
| 37  | NR_003017   | SNORA71C  | -1.12            | 2.17            |
| 38  | NM_006111   | ACAA2     | -1.11            | 2.16            |
| 39  | NR_000024   | SNORD46   | -1.11            | 2.15            |
| 40  | NR_004380   | SNORD104  | -1.10            | 2.15            |
| 41  | NM_000599   | IGFBP5    | -1.09            | 2.14            |
| 42  | NR_002450   | SNORD68   | -1.09            | 2.13            |
| 43  | NM_001030   | RPS27     | -1.09            | 2.12            |
| 44  | NR_029707   | MIR186    | -1.08            | 2.12            |
| 45  | NR_002922   | SNORA13   | -1.08            | 2.11            |
| 46  | NR_000012   | SNORA68   | -1.07            | 2.10            |
| 47  | NM_001170423| PRSS35    | -1.07            | 2.10            |
| 48  | NM_001030   | RPS27     | -1.07            | 2.10            |
| 49  | NR_002961   | SNORA22   | -3.50            | 11.32           |
| 50  | NR_002751   | SNORD41   | -2.93            | 7.63            |
| 51  | NM_020299   | AKR1B10   | -2.41            | 5.31            |
| 52  | NR_003925   | RNU4-1    | -2.02            | 4.05            |
| 53  | NR_002753   | RNU5F     | -1.89            | 3.71            |
| 54  | NM_016097   | IER3IP1   | -1.07            | 2.10            |
**HOXA10 selectively regulates the nuclear function of PTEN through EGR1**

After knockdown with iHOXA10, RT-PCR data showed significant suppression of EGR1 and PTEN in both LN18 (93% and 30% suppression) and LN229 (25% and 58% suppression) cells (Figure 4). These results suggested that EGR1 and PTEN are the mediators regulated by HOXA10 status. However, suppression of PTEN induced by iHOXA10 did not affect the phosphoinositide 3-kinase (PI3K) pathway. The protein expression of total Akt and phosphorylated Akt showed no change, although PTEN was suppressed by iHOXA10 (Figure 5). This finding implies that HOXA10 regulates only the nuclear function of PTEN without affecting its cytoplasmic function. This finding was also supported by the result of the cell viability test involving inhibition of PTEN directly with siRNA (iPTEN) that suppresses the cytoplasmic function of PTEN. No significant difference in cell death rate was noted whether iPTEN was added or not to TMZ, although significant differences were observed with the iHOXA10 and TMZ combination (Figure 6).
Figure 4

RT-PCR result after HOXA10 knockdown by siRNA. Reduction of expression in EGR1 and PTEN are shown.
Figure 5

Western blot result after HOXA10 knockdown by siRNA. In spite of the suppression of PTEN, both total Akt and phosphorylated Akt remained without change in expression.
Figure 6

Result of cell viability test presented by relative cell death ratio. Direct inhibition of PTEN (inhibition of cytoplasmic function of PTEN) shows no influence on anticancer effect of temozolomide, although inhibition of HOXA10 (indirect inhibition of nuclear function of PTEN) shows additive anticancer effect with temozolomide in both cell lines.
Impairment of the HR system was observed with HOXA10 inhibition

We further validated the association of the regulatory activity of HOXA10 with the nuclear function of PTEN—namely, the maintenance of the HR system via the positive transcriptional regulation of Rad51 genes. Significant downregulation of all Rad51b, Rad51c, and Rad51d genes was found after HOXA10 knockdown (Figure 7). Next, the formation of γ-H2AX at the site of double-strand DNA damage was checked. The kinetics of γ-H2AX foci is a well-accepted surrogate marker of the function of the HR system, which repairs DNA-double strand breakage. A significant increase in the number of γ-H2AX foci was demonstrated in iHOXA10-treated cells (Figure 8), indicating that inhibition of HOXA10 impairs the HR DNA repair system, potentially keeping cancer cells from escaping death after anticancer treatment. The apoptosis assay confirmed that a significantly increased number of cancer cells undergo apoptosis after treatment with both iHOXA10 and temozolomide (Figure 9).
Figure 7

RT-PCR result after HOXA10 knockdown by siRNA. Reduction of expression in Rad51b, Rad51c and Rad51d are shown.
Figure 8

Immunofluorescence image of γ-H2AX foci which indicates double strand DNA breakage. Increased numbers of γ-H2AX foci are seen with HOXA10 inhibition.
Figure 9

Annexin V apoptosis assay shows significant increase of apoptosis in cancer cell lines by HOXA10 inhibition in combination with temozolomide.
DISCUSSION

Homeobox genes are essential developmental regulators, some of which are normally expressed during embryogenesis but are frequently up-regulated in cancer cells \(^\text{28}\). In the normal adult brain, most HOX genes are not expressed at all or are expressed at very low levels \(^\text{13}\). However, reports have demonstrated increased expression of HOX genes in brain tumors as well as other cancers from various organs \(^{16,28-34}\). Murat et al. reported coordinated data of HOX genes and treatment resistance in GBM samples \(^\text{10}\). They found that high HOXA10 expression was predictive of resistance of treatment, including TMZ treatment, independent of the MGMT methylation status of the tumor \(^\text{10}\). The HOX genes aberrantly expressed in cancer cells are considered to be tumor modulators rather than tumor suppressor genes or oncogenes \(^{28}\). Recent studies concerning the functional analysis of HOX genes in glioblastoma also corroborate this assertion \(^{9,18}\). Costa et al. demonstrated that HOXA9 plays oncogenic effects in GBM, such as inhibiting apoptosis and increasing cell proliferation, both of which can be reversed by inhibiting the PI3K pathway through an epigenetic mechanism involving histone H3K27 trimethylation \(^{18}\). They also showed that HOXA9 is an independent negative prognostic factor of survival; interestingly, HOXA9 expression remained a valid prognostic factor in the methylated MGMT promoter subgroup \(^{18}\). They suggested
that the suppression of oncogenic HOXA expression by mTOR- or PI3K-targeted therapies can be a possible anticancer therapy for GBM patients \(^\text{18}\). Gaspar et al. reported a similar study with a more specific focus on treatment resistance \(^\text{9}\). They found high expression levels of the HOXA9/HOXA10 genes in pediatric GBM patient samples as well as a TMZ-resistant pediatric GBM cell line; high HOXA9/HOXA10 levels were related to shorter survival \(^\text{9}\). Temozolomide resistance in the high HOXA9/HOXA10-expressing GBM cell line was independent of MGMT status, and the PI3K pathway was considered to be an upstream regulator of HOX genes that can be targeted to overcome the resistance \(^\text{9}\). However, neither study investigated the downstream mechanism of temozolomide resistance induced by HOX genes.

In the present study, based on our hypothesis and related experimentation, we confirmed the downstream mechanism of HOXA10 associated with temozolomide resistance. In summary, HOXA10 induces transcription of EGR1, which sequentially results in PTEN expression. PTEN in the nucleus then acts as a positive transcriptional regulator of Rad51 paralogs, which are essential for the maintenance of the HR DNA repair system, which can protect cancer cells from temozolomide-induced cytotoxicity. Thus, inhibition of HOXA10 can downregulate EGR1, PTEN, and Rad51 paralogs in serial order to interfere with the HR system of cancer cells, making the
cancer cell more vulnerable to temozolomide treatment. These processes occur at the nuclear level, and thus, the inhibition of HOXA10 does not affect the tumor suppressor function of PTEN that occurs in the cytoplasm. Studies have proposed novel nuclear functions of PTEN, including transcription regulation, other than its classical role of repressing the PI3K/Akt pathway. McEllin et al. have also shown that PTEN has a novel nuclear function of transcriptional regulation of the Rad51 gene. They also mentioned that downregulation of HR due to PTEN loss would result in sensitivity to DNA alkylating agents or PARP inhibitors. The role of EGR1 as a mediator of PTEN regulation has been proposed in multiple studies. The PTEN pathway is regulated at multiple different levels. Among them, p53, IGF2, PPARγ, and EGR1 are molecules that can directly act on the promoter of PTEN to activate transcription. Taken together, all the above lines of evidence, including our results, support the integrity of the EGR1-PTEN-Rad51 axis for HR system regulation initiated by HOXA10.

TMZ has been reported to be a strong double-strand DNA break inducer with a potency more than 10-fold that of ionizing radiation. Although studies have indicated that molecules comprising the HR system can be potential modulators of temozolomide cytotoxicity, the importance of the HR system for temozolomide resistance was not
highlighted until recently\textsuperscript{39-46}. Therefore, the status of HR system in cancer cells may likely be used a biomarker or target to determine the clinical response to TMZ treatment. Moreover, it is also important to consider the MGMT status together with the HR system status because the concepts of oncogenic addiction and synthetic lethality can be applied\textsuperscript{47}. For example, the possibility exists for the augmentation of MMR and the HR system in cancer cells with MGMT in an inactive state, such as in GBM with a methylated MGMT promoter, which has potential to interfere with TMZ cytotoxicity. In that case, inhibition of the HR system itself may show an enhanced anticancer effect through sensitization to TMZ treatment.
CONCLUSION

Our study indicates that the HOXA10 can be a good therapeutic target as well as a biomarker to overcome TMZ resistance in the management of GBM patients.
REFERENCES

1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466.

2. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.

3. Park CK, Kim JE, Kim JY, et al. The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas. Transl Oncol 2012;5:393-397.

4. McEllin B, Camacho CV, Mukherjee B, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer research 2010;70:5457-5464.

5. Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 2012;5:102-114.

6. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009;15:4622-4629.
7. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007;13:2038-2045.

8. Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer research 2006;66:3987-3991.

9. Gaspar N, Marshall L, Perryman L, et al. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res 2010;70:9243-9252.

10. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26:3015-3024.

11. Ohgo S, Itoh A, Suzuki M, et al. Analysis of hoxa11 and hoxa13 expression during patternless limb regeneration in Xenopus. Developmental biology 2010;338:148-157.

12. Hueber SD, Lohmann I. Shaping segments: Hox gene function in the genomic age. BioEssays : news and reviews in molecular, cellular and developmental biology 2008;30:965-979.
13. Takahashi Y, Hamada J, Murakawa K, et al. Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system. Exp Cell Res 2004;293:144-153.

14. Henderson GS, van Diest PJ, Burger H, Russo J, Raman V. Expression pattern of a homeotic gene, HOXA5, in normal breast and in breast tumors. Cell Oncol 2006;28:305-313.

15. Yuan W, Zhang X, Xu Y, et al. Role of HOXB7 in regulation of progression and metastasis of human lung adenocarcinoma. Molecular carcinogenesis 2012.

16. Abdel-Fattah R, Xiao A, Bomgardner D, et al. Differential expression of HOX genes in neoplastic and non-neoplastic human astrocytes. J Pathol 2006;209:15-24.

17. Buccoliero AM, Castiglione F, Degl'Innocenti DR, et al. Hox-D genes expression in pediatric low-grade gliomas: real-time-PCR study. Cell Mol Neurobiol 2009;29:1-6.

18. Costa BM, Smith JS, Chen Y, et al. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res 2010;70:453-462.

19. Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M. PTEN gene transfer in human malignant glioma: sensitization to
irradiation and CD95L-induced apoptosis. Oncogene 1999;18:3936-3943.

20. Park CK, Kim J, Yim SY, et al. Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro-oncology 2011;13:195-202.

21. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 2009;4:44-57.

22. Su L, Cheng H, Sampaio AV, Nielsen TO, Underhill TM. EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor. Oncogene 2010;29:4352-4361.

23. Lau MT, Klausen C, Leung PC. E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression. Oncogene 2011;30:2753-2766.

24. Yu J, Zhang SS, Saito K, et al. PTEN regulation by Akt-EGR1-ARF-PTEN axis. The EMBO journal 2009;28:21-33.

25. Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007;128:157-170.

26. Yin Y, Shen WH. PTEN: a new guardian of the genome.
27. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. The Journal of biological chemistry 1998;273:5858-5868.

28. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2002;2:777-785.

29. Bodey B, Bodey B, Jr., Siegel SE, Kaiser HE. Immunocytochemical detection of the homeobox B3, B4, and C6 gene products in childhood medulloblastomas/primitive neuroectodermal tumors. Anticancer Res 2000;20:1769-1780.

30. Buccoliero AM, Castiglione F, Rossi Degl'Innocenti D, et al. Hox-D genes expression in pediatric low-grade gliomas: real-time-PCR study. Cellular and molecular neurobiology 2009;29:1-6.

31. Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene 2007;26:6766-6776.

32. Cillo C, Barba P, Freschi G, et al. HOX gene expression in normal and neoplastic human kidney. International journal of cancer. Journal international du cancer 1992;51:892-897.

33. De Vita G, Barba P, Odartchenko N, et al. Expression of homeobox-containing genes in primary and metastatic colorectal cancer. European journal of cancer 1993;29A:887-893.

34. Bahrani-Mostafavi Z, Tickle TL, Zhang J, et al. Correlation
analysis of HOX, ErbB and IGFBP family gene expression in ovarian cancer. Cancer Invest 2008;26:990-998.

35. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008;133:403-414.

36. Sarver AL, Li L, Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer research 2010;70:9570-9580.

37. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010;16:4325-4330.

38. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010;31:955-960.

39. Knizhnik AV, Roos WP, Nikolova T, et al. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PloS one 2013;8:e55665.

40. Eich M, Roos WP, Dianov GL, Digweed M, Kaina B. Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide. Molecular pharmacology 2010;78:943-951.

41. Quiros S, Roos WP, Kaina B. Rad51 and BRCA2--New
molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PloS one 2011;6:e27183.

42. Short SC, Giampieri S, Worku M, et al. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. Neuro-oncology 2011;13:487-499.

43. Caporali S, Falcinelli S, Starace G, et al. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Molecular pharmacology 2004;66:478-491.

44. Stojic L, Mojas N, Cejka P, et al. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes & development 2004;18:1331-1344.

45. Mirzoeva OK, Kawaguchi T, Pieper RO. The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Molecular cancer therapeutics 2006;5:2757-2766.

46. Schroering AG, Kothandapani A, Patrick SM, et al. Prolonged cell cycle response of HeLa cells to low-level alkylation exposure. Cancer research 2009;69:6307-6314.

47. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nature reviews. Cancer 2005;5:689-698.
국문 초록

서론:

테모졸로마이드 치료 저항성은 다양한 DNA 복구 기전과 관련되어 있다. 본 연구에서는 테모졸로마이드 치료 저항성 획득 기전 중, 특히 상동재조합 DNA 복구 기전에 초점을 맞추어, HOX 유전자의 역할에 대해서 분석하였다. 또한 MGMT 유전자 프로모터의 메틸화 여부에 따른 HOX 유전자의 임상적 의미에 대해 연구하였다.

방법:

서로 다른 MGMT 유전자 프로모터의 메틸화를 가진 2개의 교모세포종 세포주를 이용하여, HOXA10 유전자의 억제에 따른 테모졸로마이드 항암요법의 치료 저항성의 차이에 대하여 연구하였다. 또한 교모세포종 세포주 실험을 통하여 RNA 간섭에 따른 유전자 발현의 차이를 분석하여 치료 저항성 획득 기전에 관한 연구를 진행하였다.

결과:

HOXA10 유전자의 억제는 각각의 세포주에 있어서 MGMT 프로모터 메틸화 여부에 상관없이 테모졸로마이드의 치료 감수성을 증가시키는 결과를 얻었으며, 이러한 치료감수성의 증가 기전은
Rad51 상동체의 하향조절로부터 얻어지는 DNA 손상 복구 과정의 결손과 관련이 있는 것으로 연구되었다. 특히, EGR1과 PTEN 유전자는 HOXA10 유전자와 상동재조합 DNA 복구기전 사이를 조절하는 중요한 매개 역할을 하고 있음을 확인할 수 있었다. 또한 HOXA10 유전자의 발현 억제는, 세포질내에서 이뤄지는 phosphoinositide 3-kinase / Akt 경로와는 무관하게 PTEN 유전자의 핵내 발현에만 선택적으로 작용하는 것으로 연구되었다.

결론:
본 연구에서 분석된 HOXA10 유전자에 의한 상동재조합 DNA 복구기전의 조절은 교모세포종 환자에 있어서 테모졸로마이드의 치료 저항성 극복을 위한 새로운 치료 전략이 될 수 있음을 보여주는 것이라 할 수 있었다.

------------------------
주요어 : HOXA10, 테모졸로마이드 저항성, 상동재조합, EGR1, PTEN
학번 : 2010-31140